Skip to main content
SpringerLink
Log in

Gliflozine bei Typ‑2‑Diabetes und Fettlebererkrankung

Gliflozins in type 2 diabetes and fatty liver disease

  • Journal Club
  • Published:
Die Diabetologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Akuta N, Watanabe C, Kawamura Y, Arase Y, Saitoh S, Fujiyama S et al (2017) Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun 1:46–52

    Article  CAS  Google Scholar 

  2. Akuta N, Kawamura Y, Watanabe C, Nishimura A, Okubo M, Mori Y et al (2019) Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Res 49:531–539

    Article  CAS  Google Scholar 

  3. Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M et al (2020) SGLT2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: the long-term effects on clinical features and liver histopathology. Intern Med 59:1931–1937

    Article  CAS  Google Scholar 

  4. Lai LL, Vethakkan SR, Mustapha NNR, Mahadeva S, Chan WK (2020) Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci 65:623–631

    Article  CAS  Google Scholar 

  5. Takahashi H, Kessoku T, Kawanaka M, Nonaka M, Hyogo H, Fujii H et al (2022) Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Epatol Commun 6:120–132

    CAS  Google Scholar 

  6. Simon TG, Roelstraete B, Khalili H, Hagström H, Ludvigsson JF (2021) Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 70:1375–1382

    Article  Google Scholar 

  7. Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, et al. Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study. Clin Gastroenterol Hepatol. https://doi.org/10.1016/j.cgh.2022.01.002. [Epub ahead of print]

Download references

Author information

Authors and Affiliations

  1. Institut für Klinische Diabetologie, Deutsches Diabetes-Zentrum, Leibniz-Zentrum für Diabetes-Forschung an der Heinrich-Heine-Universität, Auf’m Hennekamp 65, 40225, Düsseldorf, Deutschland

    S. Kahl

Authors
  1. S. Kahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Kahl.

Ethics declarations

Interessenkonflikt

S. Kahl gibt an, dass kein Interessenkonflikt besteht.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kahl, S. Gliflozine bei Typ‑2‑Diabetes und Fettlebererkrankung. Diabetologie 18, 665–666 (2022). https://doi.org/10.1007/s11428-022-00922-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-022-00922-4

Search

Navigation